Skip to content

DR. BOYDENS

Active Private limited companyfounded 2009active for 17 yearsKerkdreef 18, 8570 AnzegemKBO/BCE: BE 0818.120.368

Lifetime

16 annual accounts with figures on one time axis
peak of €127,946 in 2025
€127,946▲ 33.9%
lowest -€4,143 in 2011
€85,097▲ 39.0%
peak of €417,444 in 2024
€401,941▼ 3.7%
€74,917▲ 35.8%
peak of 1 FTE in 2014
-not published
Board2 names since 2009
2 directors and 1 other
Documentsfilings and deeds
31-01-2026on the last day
2025micro format
Gross margin from €95,588 to €127,946Result from €61,234 to €85,097Dividend €100,600Debts from €55,150 to €74,917Investments €23,580

Key points

from the 2025 annual accounts

Equity

€401,941 ▼ 3.7%
417,4442024+85,097Profit-100,600Dividend401,9412025

DR. BOYDENS paid out €100,600 in dividends. That is 118% of the 2025 profit.

Turnover

≈ €320,000 estimated

The micro format states no turnover.

Investments

€33,885 7.3 times depreciation
20232025

Green is investment, beige is depreciation. Machinery stands 164.6% higher than in 2024.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,827 companies had the same profile as DR. BOYDENS has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,827 companies, not a prediction for DR. BOYDENS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
Director
  • 186 sharesdeed of 08-09-2009
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0818120368
1 director appointed, 1 resignation, 1 reappointment resigns as statutory director · reappointed as statutory director · appointed as statutory director · General meeting of 17-10-2023 · Gazette deed
Publication in the Belgian Official Gazette Capital €12,400, annual accounts 2011 · Gazette deed
Incorporation Founding capital of €18,600, 186 shares, €12,400 paid up · Founded by ) · ) appointed as sole statutory manager and partner · published on 08-09-2009 · Gazette deed
All 28 events

Official details

Source: KBO
Status
Active since 26-08-2009Normal situation
Activity
General medical practiceNACE 862101 activity on the establishment unitFrom the articles, 2 activities
Establishment unit
2.182.230.1808570 Anzegem, since 26-08-2009
Financial year end
30 June
Peppol
Reachable since 18-12-2025
Company details

Annual accounts to 30-06-2025

€476,858▲ 0.9%
Filing
Filed on 31-01-2026, on the last day of the filing period
Financials

Insights on DR. BOYDENS

DR. BOYDENS files the micro format. That format states no turnover. The gross margin rose from €27,670 in 2010 to €127,946 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DR. BOYDENS

What is the company number of DR. BOYDENS?
The company number of DR. BOYDENS is 0818.120.368. The VAT number is the same number with BE in front: BE 0818.120.368.
Where is DR. BOYDENS based?
The registered office is at Kerkdreef 18, 8570 Anzegem.Company details
What does DR. BOYDENS do?
According to the KBO register, the main activity of the establishment unit is general medical practice (NACE 86210).
What is the legal form of DR. BOYDENS?
DR. BOYDENS is a private limited company (BV).
When was DR. BOYDENS founded?
DR. BOYDENS was founded on 26-08-2009.
Is DR. BOYDENS still active?
Yes, DR. BOYDENS is an active enterprise in the KBO register.
What is the turnover of DR. BOYDENS?
The turnover in financial year 2025 is about €320,000. This figure is estimated from the gross margin of €127,946 and 2,451 comparable companies of the same size. It probably lies between €210,000 and €490,000. It is a rough estimate.Financials
Is DR. BOYDENS profitable?
In financial year 2025, DR. BOYDENS made a profit of €85,097.
Where can I find the annual accounts of DR. BOYDENS?
DR. BOYDENS filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DR. BOYDENS due?
DR. BOYDENS must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.